Treatment of aggressive prostate cancer with triptorelin in real life in France: the TALISMAN study.

ABSTRACT:

Background

Data on modalities of real-world use of androgen deprivation therapy, such as triptorelin, in men with prostate cancer (PCa) are lacking.

Objectives

To describe the real-world management of triptorelin treatment over 12 months following treatment initiation in France, and to gain a better understanding of the choices being made about planned total treatment duration, formulation, and route of administration.

Design

TALISMAN was a prospective, multicenter, longitudinal, non-interventional study.

Methods

Patients with PCa eligible for triptorelin treatment for at least 12 months were enrolled and followed up for 12 months. The primary objective was to describe the proportion of patients treated continuously with triptorelin during the 12 months followi

SUBMITTER: Lebret T 

PROVIDER: S-EPMC12536108 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature